Countable Labs announces Ancora assays for molecular testing of hematologic malignancy, marking the company's entry into clinical markets.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented ...

EVANSTON, Ill.--(BUSINESS WIRE)--Minute Molecular Diagnostics today announced that the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for its rapid DASH ...

As food brands and restaurants usher in the festive season with increasing footfalls during celebrations, food safety becomes ...

Co-Diagnostics Inc. ( CODX ), a molecular diagnostics company developing patented PCR-based testing technology, has entered a collaboration with ReadyGo Diagnostics Ltd. to evaluate blood-based ...

Co-Diagnostics has filed a Dual 510(k) premarket notification with the US Food and Drug Administration (FDA) for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test, run on the Co-Dx PCR Pro ...

Many people will have experienced being unwell with an unknown infection and having to undergo multiple tests to determine the culprit. This sequential process of elimination can be time-consuming and ...

Detailed price information for Co-Diagnostics Inc (CODX-Q) from The Globe and Mail including charting and trades.

The molecular diagnostics market size is valued at USD 17.6 billion in 2025 and is projected to reach USD 36.2 billion by the end of 2035, with a compound annual growth rate (CAGR) of 7.4% during the ...

New research shows a blood test can detect returning breast cancer months to years before scans or symptoms appear.

Macrolide antibiotics such as azithromycin have long been the cornerstone of treatment for Mycoplasma pneumoniae, a leading ...

Co-Diagnostics, Inc. announced that the companies are collaborating to evaluate the potential use of ReadyGo Diagnostics Ltd.'s sample-preparation technology with the Co-Dx PCR platform for ...